Biologic therapy for psoriasis: The tumor necrosis factor inhibitors - Infliximab and etanercept

被引:0
|
作者
Weinberg, JM
机构
[1] St Lukes Roosevelt Hosp, Dept Dermatol, New York, NY 10025 USA
[2] Beth Israel Med Ctr, Dept Dermatol, New York, NY 10003 USA
来源
CUTIS | 2003年 / 71卷 / 01期
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
This article has been peer reviewed and approved,by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine Review date December 2002, December. This activity has been planned and implemented in accordance with the Essential Area's and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship, of Albert Einstein College of Medicine and :Quadrant HealthCom, Inc. The Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Albert Einstein College of Medicine designates this educational activity for a in category, 1 credit toward the AMA Physician's Recognition. Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. This activity has been planned and produced in accordance with ACCME Essentials.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 50 条
  • [1] An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis
    Weinberg, JM
    CLINICAL THERAPEUTICS, 2003, 25 (10) : 2487 - 2505
  • [2] Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors
    Campanati, Anna
    Molinelli, Elisa
    Brisigotti, Valerio
    Offidani, Annamaria
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2017, 18 (12) : 945 - 963
  • [3] Combination Therapy With Tumor Necrosis Factor Inhibitors in Psoriasis Treatment
    Famenini, Shannon
    Wu, Jashin J.
    CUTIS, 2013, 92 (03): : 140 - 147
  • [4] Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α
    Mitoma, H
    Horiuchi, T
    Tsukamoto, H
    GASTROENTEROLOGY, 2004, 126 (03) : 934 - 935
  • [5] Tumor Necrosis Factor Inhibitors in Psoriasis: An Update
    Kerdel, Francisco A.
    Strober, Bruce E.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2014, 33 : S31 - S36
  • [6] Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
    Selva-O'Callaghan, Albert
    Labrador-Horrillo, Moises
    Tarres, Miguel, V
    CURRENT RHEUMATOLOGY REVIEWS, 2005, 1 (02) : 157 - 165
  • [7] Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α -: Reply
    Van den Brande, JHM
    Bratt, H
    Van Deventer, SJH
    Peppelenbosch, MP
    GASTROENTEROLOGY, 2004, 126 (03) : 935 - 936
  • [8] Tumor necrosis factor antagonists in the therapy of psoriasis
    Moessner, Rotraut
    Schoen, Michael P.
    Reich, Kristian
    CLINICS IN DERMATOLOGY, 2008, 26 (05) : 486 - 502
  • [9] Tumor Necrosis Factor Inhibitors and Myocardial Infarction in Psoriasis
    Wu, Jashin J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (10): : 1075 - 1076
  • [10] Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept
    Gindi, V
    Lowe, N
    Koo, S
    Yamauchi, P
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P200 - P200